1629041-92-4

Basic information

• Product Name: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(thiazol-2-yl)benzene sulfonamide
• CAS NO: 1629041-92-4
• Molecular Weight: 460.91
• Mol File: 1629041-92-4.mol
• Article Data: 11

Chemical Properties

• CAS DataBase Reference: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(thiazol-2-yl)benzene sulfonamide(CAS DataBase Reference)
• NIST Chemistry Reference: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(thiazol-2-yl)benzene sulfonamide(1629041-92-4)
• EPA Substance Registry System: 5-chloro-N-(2,4-dimethoxybenzyl)-2,4-difluoro-N-(thiazol-2-yl)benzene sulfonamide(1629041-92-4)

Safety Data

• Hazardous Substances Data: 1629041-92-4(Hazardous Substances Data)

Upstream product

• 613-45-6 2,4-Dimethoxybenzaldehyde 
• 853994-53-3 N-(2,4-dimethoxybenzyl)-N-(1,3-thiazol-2-yl)amine 
• 13656-57-0 5-chloro-2,4-difluorobenzene-1-sulfonyl chloride 

Relevant articles and documents

Discovery of non-zwitterionic aryl sulfonamides as Nav1.7 inhibitors with efficacy in preclinical behavioral models and translational measures of nociceptive neuron activation

Since zwitterionic benzenesulfonamide Nav1.7 inhibitors suffer from poor membrane permeability, we sought to eliminate this characteristic by replacing the basic moiety with non-basic bicyclic acetals and monocyclic ethers. These efforts led to

DIAMINO-ALKYLAMINO-LINKED ARYLSULFONAMIDE COMPOUNDS WITH SELECTIVE ACTIVITY IN VOLTAGE-GATED SODIUM CHANNELS

Disclosed are compounds of Formula A, or a salt thereof: Formula (A), wherein: Het, Q and R1A to R4A are defined herein, which compounds have properties for blocking Nav 1.7 ion channels found in peripheral and sympathetic

BENZENESULFONAMIDE COMPOUNDS AND THEIR USE AS THERAPEUTIC AGENTS

This invention is directed to benzenesulfonamide compounds, as stereoisomers, enantiomers, tautomers thereof or mixtures thereof; or pharmaceutically acceptable salts, solvates or prodrugs thereof, for the treatment of diseases or conditions associated with voltage-gated sodium channels, such as epilepsy and/or epileptic seizure disorders.